The study began in December 2023 with estimated completion in May 2026 and is currently actively recruiting across multiple international sites, with Phase 1 healthy volunteer data showing favorable safety profile, dose-proportional pharmacokinetics with 2-week half-life, and approximately 50% reduction in PD-1 expressing CD4+ and CD8+ T cells lasting over 30 days, supporting progression to this Phase 2 efficacy trial (67)
Thyroid cancer, or a family history Type 1 Diabetes Pancreatitis Liver disease Pregnant, breast feeding, or planning to become pregnant Severe gastrointestinal disorders Kidney disease Multiple endocrine neoplasia Allergic reactions to weight loss medications People taking other medications that lower blood sugar Our providers at Elite, take screening before any procedure/medication seriously, to avoid reactions or serious side effects
Ask Omzo's team what happens to your care if compounded semaglutide or tirzepatide becomes unavailable or restricted
Buying Peptides Online: A Direct Comparison Many Jacksonville area residents have found BPC-157 online before discovering BlueWater
Makeup returns: We do not accept returns of any makeup that's been opened